Cartesian Therapeutics Inc. (RNAC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cartesian Therapeutics Inc. (RNAC) has a cash flow conversion efficiency ratio of 0.149x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.14 Million) by net assets ($-148.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cartesian Therapeutics Inc. stock valuation for the company's overall valuation and market capitalisation.
Cartesian Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Cartesian Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View RNAC stock price and chart for real-time trading data and today's change.
Cartesian Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cartesian Therapeutics Inc. ranked by their cash flow conversion efficiency. Review free cash flow generation of Cartesian Therapeutics Inc. to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polymetals Resources Ltd
AU:POL
|
-1.678x |
|
Jacob Finance And Investments Ltd
TA:JCFN
|
0.069x |
|
Bhageria Industries Limited
NSE:BHAGERIA
|
0.048x |
|
New World Resources Ltd
AU:NWC
|
-0.015x |
|
5paisa Capital Ltd
NSE:5PAISA
|
-0.098x |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
-0.166x |
|
Quercus TFI SA
WAR:QRS
|
0.557x |
|
ST.GEORGE MINING LTD
F:S0G
|
N/A |
Annual Cash Flow Conversion Efficiency for Cartesian Therapeutics Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Cartesian Therapeutics Inc. from 2014 to 2025. Also see balance sheet size of Cartesian Therapeutics Inc. for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-126.24 Million | $-73.94 Million | 0.586x | -83.17% |
| 2024-12-31 | $-6.80 Million | $-23.67 Million | 3.480x | +2894.54% |
| 2023-12-31 | $-440.18 Million | $-51.16 Million | 0.116x | +134.48% |
| 2022-12-31 | $93.83 Million | $-31.63 Million | -0.337x | +87.43% |
| 2021-12-31 | $22.52 Million | $-60.38 Million | -2.681x | -38.40% |
| 2020-12-31 | $-18.01 Million | $34.88 Million | -1.937x | +68.37% |
| 2019-12-31 | $8.40 Million | $-51.44 Million | -6.125x | -156.10% |
| 2018-12-31 | $-5.42 Million | $-59.16 Million | 10.919x | +1187.25% |
| 2017-12-31 | $51.81 Million | $-52.04 Million | -1.004x | -180.41% |
| 2016-12-31 | $54.96 Million | $-19.68 Million | -0.358x | -285.74% |
| 2015-12-31 | $-116.49 Million | $-22.46 Million | 0.193x | +33.39% |
| 2014-12-31 | $-87.75 Million | $-12.69 Million | 0.145x | -- |
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune disease… Read more